Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Fabry Disease
Interventions: PRX-102 (pegunigalsidase alfa), agalsidase beta; Biological
Lead sponsor: Protalix; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 11 more

Conditions: Osteoarthritis, Acetaminophen, Arthroplasty, Hip Replacement
Interventions: Intravenous acetaminophen, Oral acetaminophen; Drug
Lead sponsor: Duke University; Other
Eligibility: 56 Years to 85 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Elevated Intraocular Pressure
Interventions: Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%; Drug
Lead sponsor: TearClear Corp; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 20
States / cities: Garden Grove, California • Glendale, California • Mission Hills, California + 16 more

Conditions: Autoimmune Haemolytic Anaemia
Interventions: rilzabrutinib, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 27
States / cities: Phoenix, Arizona • Tucson, Arizona • Duarte, California + 23 more

Conditions: Urine Detectable Acute and Chronic Diseases
Interventions: Dip Home-Based Dipstick Analyzer, Urine analysis predicate device for professional user; Diagnostic Test · Device
Lead sponsor: Healthy.io Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 429 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 3
States / cities: Atlanta, Georgia • Methuen, Massachusetts • Garden City, New York

Conditions: Alzheimer Disease
Interventions: BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 55 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 17
States / cities: Colton, California • Long Beach, California • Redlands, California + 12 more

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention; Procedure · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 25 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Down Syndrome, Down Syndrome (Trisomy 21)
Interventions: Mindfulness-Based Therapy for Insomnia, Wait-list control; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 12 Months to 30 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Yellow Fever, Healthy Volunteers
Interventions: Yellow fever vaccine (produced on serum-free Vero cells), Yellow fever vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 568 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 11
States / cities: Decatur, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 8 more

Conditions: Cervical Radiculopathy, Myelopathy
Interventions: Anterior Cervical Discectomy and Fusion; Procedure
Lead sponsor: LifeNet Health; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Gastroesophageal Reflux
Interventions: Nissen fundoplication; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: Up to 24 Months
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Long COVID
Interventions: Nirmatrelvir, Ritonavir, Placebo; Drug
Lead sponsor: Harlan M Krumholz; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alveolar Bone Loss
Interventions: Freeze-Dried Bone Allograft control, Mineralized Dentin Graft, Partial-Demineralized Dentin Graft; Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Older Aged Adults; Balance
Interventions: Tai-chi prime (TCP); Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 65 Years and older
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: La Crosse, Wisconsin • Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Covid19
Interventions: Disulfiram, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Fresno, California • San Francisco, California

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency, Iron-deficiency Anemia (IDA)
Interventions: Ferric Carboxymaltose, Ferrous Sulfate; Drug
Lead sponsor: Syed Hamza Mufarrih; Other
Eligibility: 18 Years to 100 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bowling Green, Kentucky

Conditions: Diabetes Mellitus, Type 2
Interventions: Glargine insulin, NPH insulin and regular insulin, lispro insulin; Drug
Lead sponsor: Cook County Health; Government
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: ADHD
Interventions: PRC-063 oral capsules, Placebo oral capsules; Drug
Lead sponsor: Purdue Pharma, Canada; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Bradenton, Florida • Lakeland, Florida • Maitland, Florida + 5 more

Conditions: Pain, Mood, Patient Satisfaction, Scheduled Cesarean Sections
Interventions: Lavender-sandalwood aromatherapy tabs; Other
Lead sponsor: Memorial Hermann Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy, Hypoxia
Interventions: Not listed
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Obesity
Interventions: Behavioral weight loss intervention; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hookworm Infection
Interventions: Na-ASP-2/Alhydrogel Hookworm Vaccine, Saline placebo; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Bipolar Disorder
Interventions: Not listed
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 15 Years to 25 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 20
States / cities: Culver City, California • Lemon Grove, California • Los Angeles, California + 17 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Metformin XR, Dapagliflozin, Placebo matching with Dapagliflozin, Placebo matching with Saxagliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 80
States / cities: Birmingham, Alabama • Homewood, Alabama • Muscle Shoals, Alabama + 73 more

Search by objective public record fields.

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

Intravenous Versus Oral Acetaminophen in Primary Total Hip Arthroplasty

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

A Comparative, Controlled Study to Evaluate the Lay User Accuracy and Performance of the Dip Home-Based Dipstick Analyzer

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

Sleep Intervention and Quality of Life in Down Syndrome

Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA

Safety Study of Preservon-Treated Bone Implants for Cervical Fusion in the Treatment of Cervical Radiculopathy or Myelopathy

Clinical Trial Comparing Open and Laparoscopic Nissen Fundoplication in Children

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

Mineralized and Partial Demineralized Dentin Graft Compared to FDBA

Improving Balance for Older Adults: Disseminating Tai Chi Fundamentals Through Community Organizations

DISulfiram for COvid-19 (DISCO) Trial

IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches

Insulin Therapy in the Hospital Comparing Two Protocols

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Lavender Sandalwood Aromatherapy Study

Controlled Acute Hypoxia Study - Abbreviated Sensor Line

Cell Phone Intervention in Young Adults

Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection

A Study of the Relationship of Psychosocial Function With Mood Symptoms in Offspring of Parents With Bipolar Disorder

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes